Chronic Hepatitis C Virus is the cause of liver cirrhosis worldwide and patients with cirrhosis secondary to chronic HCV infection are at increased risk for developing Hepatocellular carcinoma. It is a disease in which Interferon therapy with or without ribavirin is the only effective anti-viral therapy. Intercellular adhesion molecule-1 (ICAM-1) is a marker of inflammation and tissue damage, in recent years, attention has been focused on the role of ICAM-1 expression in a variety of inflammatory, autoimmune and malignant disease. Prediction of response to interferon alpha therapy may help eliminate the needless and expensive treatment. Thus this study aimed to investigate cellular expression of Intercellular adhesion molecule-1 (ICAM-1) as an early prognostic marker for the response of chronic hepatitis C patients to anti-viral treatment by interferon with or without Ribavirin. This study included 20 patients suffering from chronic hepatitis C viral infection and were received interferon therapy with Ribavirin for 6 –12 months. After treatment, their PCR results turn into negative in 19 patients (the responders) as well as the ICAM-1 expression turn into the normal level & still PCR positive in one patient (non responder) with high ICAM-1 level expression.